View More View Less
  • 1 Chemistry Division, Directorate of Science, Pakistan Institute of Nuclear Science and Technology, P.O. Nilore, Islamabad, 45650 Pakistan
Restricted access

Abstract  

To understand the role of Cu and Zn in human blood both in controls as well as in cardiovascular (CVD) patients, whole blood samples of 181 CVD and 185 controls between the ages of 20–66 years were investigated. Instrumental neutron activation analysis (INAA) and flame atomic absorption spectrophotometric techniques were successfully employed to quantification Cu and Zn levels. The mean blood-Cu levels (1.50 mg L−1) were found as enhanced whereas Zn levels (5.88 mg L −1) were reduced in cardiovascular patients group as compared to 0.90 and 6.70 mg L−1 for Cu and Zn respectively in controls. Cu/Zn ratios for CVD patients are also higher than in control subjects. Negative correlation exists between Cu and Zn levels in both controls and patient groups. However, when the CVD patients were checked for their systolic and diastolic pressure it was found that copper concentrations in these patients was significantly increased (p < 0.001) with the rise of blood systolic pressure so a positive correlation was observed between copper and systolic pressure. Zn on the other hand has an inverse relation with systolic as well as diastolic pressure (p < 0.001). Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, and triglyceride (TG) in blood samples have also been determined and their probable role in the CVD complication has been observed. A positive correlation of blood-Cu with TC, TG, and LDL-C indicates that rise in blood-Cu levels may initiate the development of CVD. An increase in Cu/Zn ratio can instigate the cardiovascular risk factor. The findings from this study can definitely update our knowledge of the role of Cu and Zn in the development of CVD risk in humans.

Manuscript Submission: HERE

  • Impact Factor (2019): 1.137
  • Scimago Journal Rank (2019): 0.360
  • SJR Hirsch-Index (2019): 65
  • SJR Quartile Score (2019): Q3 Analytical Chemistry
  • SJR Quartile Score (2019): Q3 Health, Toxicology and Mutagenesis
  • SJR Quartile Score (2019): Q2 Nuclear Energy and Engineering
  • SJR Quartile Score (2019): Q3 Pollution
  • SJR Quartile Score (2019): Q3 Public Health, Environmental and Occupational Health
  • SJR Quartile Score (2019): Q3 Radiology, Nuclear Medicine and Imaging
  • SJR Quartile Score (2019): Q3 Spectroscopy
  • Impact Factor (2018): 1.186
  • Scimago Journal Rank (2018): 0.408
  • SJR Hirsch-Index (2018): 60
  • SJR Quartile Score (2018): Q2 Nuclear Energy and Engineering
  • SJR Quartile Score (2018): Q2 Pollution

For subscription options, please visit the website of Springer Nature.

Journal of Radionalytical and Nuclear Chemistry
Language English
Size A4
Year of
Foundation
1968
Volumes
per Year
4
Issues
per Year
12
Founder Akadémiai Kiadó
Founder's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Publisher Akadémiai Kiadó
Springer Nature Switzerland AG
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
CH-6330 Cham, Switzerland Gewerbestrasse 11.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 0236-5731 (Print)
ISSN 1588-2780 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
May 2021 0 0 0
Jun 2021 0 0 0
Jul 2021 0 0 0
Aug 2021 2 0 0
Sep 2021 1 0 0
Oct 2021 1 0 0
Nov 2021 0 0 0